Richardson, P. G., Lee, H. C., Abdallah, A., Cohen, A. D., Kapoor, P., Voorhees, P. M., . . . Lonial, S. (2020). Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: Analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J.
Chicago-stil citatRichardson, Paul G., et al. "Single-agent Belantamab Mafodotin for Relapsed/refractory Multiple Myeloma: Analysis of the Lyophilised Presentation Cohort From the Pivotal DREAMM-2 Study." Blood Cancer J 2020.
MLA-referensRichardson, Paul G., et al. "Single-agent Belantamab Mafodotin for Relapsed/refractory Multiple Myeloma: Analysis of the Lyophilised Presentation Cohort From the Pivotal DREAMM-2 Study." Blood Cancer J 2020.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.